

Surgical resection of the primary tumor improves survival in patients with pancreatic neuroendocrine tumors associated with liver metastases: a meta-analysis

La resección quirúrgica del tumor primario mejora la supervivencia en pacientes con tumores neuroendocrinos pancreáticos asociados a metástasis hepáticas: un metaanálisis

Jiuting Zhu¹, Yang Zhang², and Wubin Wang^{1*}

¹Department of General Surgery; ²Department of Gastroenterology. Ningbo No. 2 Hospital, Ningbo, China

Abstract

Objective: The role of palliative pancreatic neuroendocrine tumor resection (pPanNEN-R) is controversial. The aim of this study was to conduct a meta-analysis of relevant studies to compare pPanNEN-R and non-surgical management (PanNEN-nR). **Methods:** All studies published until May 31, 2024, comparing pPanNEN-R and PanNEN-nR were reviewed. The primary outcome was overall survival (OS). Meta-analysis was performed after the data extraction process. **Results:** A total of 10 studies and 1152 patients were included, of whom 373 (32.38%) received pPanNEN-R, and 779 (67.62%) received PanNEN-nR. The overall quality of the included studies was fair. Patients receiving pPanNEN-R had a significantly lower risk of death compared with those receiving PanNEN-nR (odds ratio = 0.32, 95% confidence interval [0.24-0.43], $p < 0.00001$). **Conclusions:** The use of pPanNEN-R in patients with unresectable liver metastases seems to be associated with a better OS compared to non-surgical treatments, but due to the limitations of the included studies, no firm conclusions can be drawn.

Keywords: Primary tumor resection. Pancreatic neuroendocrine tumor. Liver metastases. Overall survival. Meta-analysis.

Resumen

Objetivo: El papel de la resección paliativa de tumores neuroendocrinos pancreáticos (pPanNEN-R) es controvertido. El objetivo de este estudio fue realizar un metaanálisis de los estudios pertinentes para comparar la resección neuroendocrina pancreática paliativa y el tratamiento no quirúrgico (resección neuroendocrina pancreática no paliativa [PanNEN-nR]). **Métodos:** Se revisaron todos los estudios publicados hasta el 31 de mayo de 2024 que comparaban pPanNEN-R y PanNEN-nR. El resultado primario fue la supervivencia global. Se realizó un metaanálisis tras el proceso de extracción de datos. **Resultados:** Se incluyeron 10 estudios con 1152 pacientes, de los cuales 373 (32.38%) recibieron pPanNEN-R y 779 (67.62%) recibieron PanNEN-nR. La calidad general de los estudios incluidos fue regular. Los pacientes con pPanNEN-R tuvieron un riesgo significativamente menor de muerte en comparación con los tratados con PanNEN-nR (odds ratio: 0.32; intervalo de confianza del 95%: 0.24-0.43; $p < 0.00001$). **Conclusiones:** El uso de pPanNEN-R en pacientes con metástasis hepáticas irresecables parece asociarse a una mejor supervivencia global en comparación con el tratamiento no quirúrgico, pero debido a las limitaciones de los estudios incluidos no se pueden extraer conclusiones firmes.

Palabras clave: Resección del tumor primario. Tumor neuroendocrino pancreático. Metástasis hepáticas. Supervivencia global. Metaanálisis.

*Correspondence:

Wubin Wang

E-mail: mydsbg@163.com

Date of reception: 12-08-2024

Date of acceptance: 27-02-2025

DOI: 10.24875/CIRU.24000432

Cir Cir. 2026;94(4):378-383

Contents available at PubMed

www.cirugiaycirujanos.com

0009-7411/© 2025 Academia Mexicana de Cirugía. Published by Permanyer. This is an open access article under the terms of the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Pancreatic neuroendocrine tumors (PNETs) are rare, with tumors accounting for only about 1% of all pancreatic tumors by incidence, although their prevalence is very close to 10%.^{1,2} The incidence of liver metastases exceeds 50% of patients affected by PNETs (80% of bilobar cases).³ In some cases, these malignancies are not amenable to resection extending to both liver lobes due to local vascular infiltration or hepatic metastases or due to extrahepatic metastases. Surgery is considered the only feasible approach to the radical treatment of metastatic PNETs, although few case series have been published.^{4,5} Since 2000, 5-year post-operative rates of hepatic resection for PNETs metastases have ranged from 74% to 100%, with disease-free survival rates ranging from 29% to 96%.⁶

Surgery for advanced metastatic PNETs seems to play a role and is recommended by international guidelines^{7,8}. Patients may choose from a variety of palliative treatment options, including radiofrequency ablation, chemotherapy, hepatic artery embolization or pharmacological treatment with octreotide or lanreotide. In addition, primary tumor resection has been recommended to alleviate symptoms related to the tumor burden or functional tumors⁸, but its prognostic effect is controversial. On the other hand, some studies have shown that primary pNETs removal could increase disease control.^{9,10}

The aim of this systematic review was to assess whether or not patients who underwent palliative PNET resection (pPanNEN-R) had an improved overall survival (OS) compared to those patients who did not undergo resection PanNEN-nR.

Methods

Search strategy

PubMed, Web of Knowledge, Medline, Ovid's database were searched from January 2005 to May 2024 with English language. The search terms used were "pancreatic neuroendocrine tumor," "liver metastases," "resection" and "survival rate." The reference lists of relevant studies were checked manually to locate any missing studies.

Study selection

Identified full papers were assessed for eligibility for inclusion in the review by scanning the titles, abstracts,

and keywords of every record retrieved. Clinical studies concerning comparisons of outcomes between the pPanNEN-R group and PanNEN-nR group were included regardless of randomized controlled trials (RCTs) or non RCTs (NRCTs). Studies were restricted to those published in English.

Data extraction

Three coauthors (JZ, WW and YZ) independently selected studies for inclusion and exclusion and reached consensus when they did not agree in the initial assignment. The following variables were recorded: authors, journal and year of publication, number of patients, age, median tumor size, histological type, surgical procedure, and 5-year OS. If necessary, the corresponding authors of studies were contacted to obtain supplementary information. The Methodological Index assessed that of the NRCTs for Nonrandomized Studies.¹¹

Statistical analysis

A formal meta-analysis was carried out for all included studies comparing the results of pPanNEN-R group and PanNEN-nR group. The outcomes in our study were OS. A fixed effects model was used to calculate a pooled odds ratio (OR) with its 95% confidence interval (CI). Heterogeneity was explored using I^2 statistics, a measure of how much the variance between studies, rather than chance, can be attributed to inter-study differences. $I^2 > 50\%$ was regarded to indicate strong heterogeneity. Begg's and Egger's tests^{12,13} were used to estimate the publication bias. Meta-analysis was conducted using STATA software, version 14.0.

Results

Study selection

A total of 87 potentially relevant titles and abstracts were obtained (Fig. 1). After exclusion of duplicate references, non-relevant literature, and those that did not satisfy the inclusion criteria, 21 candidate articles were considered for the meta-analysis. After careful review of the full text of these articles, 10 studies (Table 1)^{4,10,14-21} fulfilled the eligibility criteria. These 10 papers were retrospective clinical trials. The publication dates




Figure 1. Flowchart of the results of the literature search.

ranged from January 2001 to December 2018. Study sizes ranged from 36 to 442 patients.

Outcome measures

A total of 373 patients who underwent primary tumor resection and 779 patients who allow non-surgical management were analyzed. The 5-year OS was 48.26% in the pPanNEN-R group compared with 22.34% in the PanNEN-nR group, and the 5-year OS was significantly higher in pPanNEN-R group than in the PanNEN-nR group (OR = 0.32, 95% CI 0.24-0.43, $p < 0.00001$) (Fig. 2). The publication bias confirmed by the Begg's and Egger's tests did not appear significant ($Pr > |z| = 1.000$, $P > t = 0.795$) (Figs. 3 and 4).

Five studies reported the 30-day post-operative complications in patients who underwent pPanNEN-R, the overall complication rate reached 52.7%. Post-operative complication was mainly related to the formation of pancreatic fistula. Thirty-day readmission, length of stay, or quality of life data were not reported by any of the ten studies.

Discussion

Studies exploring the role of pPanNEN-R were considered in this review, but these studies have some limitations. These studies were not randomized trials, and almost all series were retrospective with limited sample sizes.

Surgical resection of the primary tumor site in patients with metastatic PNET is a controversial practice, especially in patients with advanced disease. In regard of primary resection, international guidelines distinguish tumor arising from the small intestine and those arising from pancreas.^{22,23} Resection of primary




Figure 2. Meta-analysis of 5-year overall survival for palliative pancreatic neuroendocrine tumor resection group versus PanNEN-non-surgical management group.




Figure 3. Begg's funnel plot for visual assessment of no publication bias for 5-year overall survival.




Figure 4. Egger's publication bias plot showed no publication bias for 5-year overall survival.

tumor is strongly recommended for intestinal tumors, whilst the resection of the primary tumor in metastatic PNETs is not recommended.²²⁻²⁴ This distinction is mainly related to the high risk of post-operative morbidity after pancreatic surgery.

Table 1. Overview on surgical and oncological outcomes reported or retrieved from included studies

Author, Year	Country	Study design	No. of patients	Sex (male/female)	Mean age (Years)	Median primary Tumor size (cm)	Type of surgery on primary tumor			Complications	Follow-up (months)	Quality score ^a
							PD	DP	Enucleation			
Bertani et al. 2013 ¹⁴	Italy	Retrospective	43	20/23	-	-	-	-	-	3/12	60	7/9
Bertani et al. 2016 ¹⁵	Italy	Retrospective	124	66/58	54.6	6.0	0	63	0	10/63	96	7/9
Bettini et al. 2009 ¹⁰	Italy	Retrospective	51	24/27	55	4.5	5	14	0	8/19	26	7/9
Citterio et al. 2016 ¹⁶	Italy	Retrospective	36	-	-	-	-	-	-	-	127	6/9
Du et al. 2015 ¹⁷	China	Retrospective	98	-	-	-	-	-	-	-	-	5/9
Hüttner et al. 2015 ¹⁸	Germany	Retrospective	442	247/195	pPanNEN-R: 52.9 PanNEN-nR: 59.6	-	-	-	-	-	pPanNEN-R: 32.5 PanNEN-nR: 17.6	7/9
Lin et al. 2018 ¹⁹	China	Retrospective	63	28/35	pPanNEN-R: 49.1 PanNEN-nR: 49.0	4.0	8	25	2	-	37	7/9
Nguyen et al. 2007 ²⁰	Italy	Retrospective	51	-	-	-	-	-	-	5/20	41	6/9
Partelli et al. 2015 ²¹	Italy	Retrospective	148	83/65	pPanNEN-R: 73 PanNEN-nR: 75	pPanNEN-R: 4.8 PanNEN-nR: 4.4	19	52	2	112/148	40.5	7/9
Solorzano et al. 2001 ⁴	USA	Retrospective	96	-	-	-	4	12	0	-	-	6/9

^aQuality scores of the included studies were assessed using the Newcastle–Ottawa Scale (NOS), with scores expressed as *actual score/maximum possible score⁹. PD: distal pancreatectomy; pPanNEN-R: palliative pancreatic neuroendocrine tumor resection; PanNEN-nR: PanNEN-non-surgical management.

However, a positive impact on prognosis after resection of the primary tumor has also been reported for PNETs. Zheng et al.²⁵ reported resection of the primary tumor was associated with prolonged survival in all patients with gastric, small intestinal, colorectal, and pancreatic neuroendocrine neoplasms with liver metastases. Tao et al.²⁶ reveals that local treatment on the primary benefits OS in PNETs patients with liver metastases. Chen et al.²⁷ illustrated primary tumor resection led to improved survival for gastrointestinal neuroendocrine carcinoma patients with non-resected liver metastases regardless of primary tumor site, tumor grade, and N stage. Our meta-analysis showed that primary tumor resection provided a significant benefit for 5-year OS in PNETs patients with liver metastases.

There are two possible explanations for the survival-prolonging effect of primary tumor resection. First, a reduction in immunosuppressive tumor burden may prolong prognosis by minimizing the chance that the tumor will lead to disease progression and further metastasis. Second, resection of the primary lesion helps to relieve symptoms of the tumor, such as bleeding, obstruction, and symptoms of tumor compression, control symptoms caused by functional tumors, and helps to focus subsequent therapy on liver metastases treatment. The actual mechanism of how primary tumor resection contributes to improved prognosis remains unclear. In the era of personalized therapy, primary tumor resection should be viewed as part of an integrated multidisciplinary approach to optimize the treatment of patients with Stage IV pancreatic neuroendocrine neoplasm.

Despite the fact that more than half of patients faced a post-operative complication, the majority of resections involved the tail of the pancreas, and surgical sequelae can usually be managed safely.

There are some limitations in our study. First, most of the included studies were retrospective chart reviews with inherent limitations such as selection bias and inaccurate or missing data reports. Second, our analysis only included published studies in English. Hence, our findings must be interpreted with caution.

Conclusions

The present study provides a meta-analysis of palliative surgical approach to patients with PNETs associated with liver metastasis, exhibiting an obvious survival benefit of primary tumor resection over time. However, the included studies were subject to selection bias. A RCTs comparing pPanNEN-R associated

with non-surgical treatment versus non-surgical treatments alone is urgently needed.

Funding

The authors declare that they have not received funding.

Conflicts of interest

The authors declare no conflicts of interest.

Ethical considerations

Protection of humans and animals. The authors declare that no experiments on humans or animals were performed for this research.

Confidentiality, informed consent, and ethical approval. This study does not involve personal patient data, medical records, or biological samples, and does not require ethical approval. SAGER guidelines do not apply.

Declaration on the use of artificial intelligence. The authors declare that no generative artificial intelligence was used in the writing or creation of the content of this manuscript.

References

1. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. *Cancer*. 2003;97:934-59.
2. Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. *J Clin Oncol*. 2008;26:3063-72.
3. Chamberlain RS, Canes D, Brown KT, Saltz L, Jarnagin W, Fong Y, et al. Hepatic neuroendocrine metastases: does intervention alter outcomes? *J Am Coll Surg*. 2000;190:432-45.
4. Solorzano CC, Lee JE, Pisters PW, Vauthey JN, Ayers GD, Jean ME, et al. Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. *Surgery*. 2001;130:1078-85.
5. Yuan CH, Wang J, Xiu DR, Tao M, Ma ZL, Jiang B, et al. Meta-analysis of liver resection versus nonsurgical treatments for pancreatic neuroendocrine tumors with liver metastases. *Ann Surg Oncol*. 2016;23:244-9.
6. Frilling A, Clift AK. Therapeutic strategies for neuroendocrine liver metastases. *Cancer*. 2015;121:1172-86.
7. Kulke MH, Anthony LB, Bushnell DL, De Herder WW, Goldsmith SJ, Klimstra DS, et al. NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas. *Pancreas*. 2010;39:735-52.
8. Steinmüller T, Kianmanesh R, Falconi M, Scarpa A, Taal B, Kwekkeboom DJ, et al. Consensus guidelines for the management of patients with liver metastases from digestive (neuro)endocrine tumors: foregut, midgut, hindgut, and unknown primary. *Neuroendocrinology*. 2008;87:47-62.
9. Capurso G, Rinzivillo M, Bettini R, Boninsegna L, Delle Fave G, Falconi M. Systematic review of resection of primary midgut carcinoid tumour in patients with unresectable liver metastases. *Br J Surg*. 2012;99:1480-6.
10. Bettini R, Mantovani W, Boninsegna L, Crippa S, Capelli P, Bassi C, et al. Primary tumour resection in metastatic nonfunctioning pancreatic endocrine carcinomas. *Dig Liver Dis*. 2009;41:49-55.
11. Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. *ANZ J Surg*. 2003;73:712-6.

12. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. *BMJ*. 1997;315:629-34.
13. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. *Biometrics*. 1994;50:1088-101.
14. Bertani E, Fazio N, Botteri E, Chiappa A, Falconi M, Grana C, et al. Resection of the primary pancreatic neuroendocrine tumor in patients with unresectable liver metastases: possible indications for a multimodal approach. *Surgery*. 2014;155:607-14.
15. Bertani E, Fazio N, Radice D, Zardini C, Spinoglio G, Chiappa A, et al. Assessing the role of primary tumour resection in patients with synchronous unresectable liver metastases from pancreatic neuroendocrine tumour of the body and tail. A propensity score survival evaluation. *Eur J Surg Oncol*. 2017;43:372-9.
16. Citterio D, Pusceddu S, Facciorusso A, Coppa J, Milione M, Buzzoni R, et al. Primary tumour resection may improve survival in functional well-differentiated neuroendocrine tumours metastatic to the liver. *Eur J Surg Oncol*. 2017;43:380-7.
17. Du S, Wang Z, Sang X, Lu X, Zheng Y, Xu H, et al. Surgical resection improves the outcome of the patients with neuroendocrine tumor liver metastases: large data from Asia. *Medicine (Baltimore)*. 2015;94:e388.
18. Hüttner FJ, Schneider L, Tarantino I, Warschkow R, Schmied BM, Hackert T, et al. Palliative resection of the primary tumor in 442 metastasized neuroendocrine tumors of the pancreas: a population-based, propensity score-matched survival analysis. *Langenbecks Arch Surg*. 2015;400:715-23.
19. Lin C, Dai H, Hong X, Pang H, Wang X, Xu P, et al. The prognostic impact of primary tumor resection in pancreatic neuroendocrine tumors with synchronous multifocal liver metastases. *Pancreatol*. 2018;18:608-14.
20. Nguyen SQ, Angel LP, Divino CM, Schluender S, Warner RR. Surgery in malignant pancreatic neuroendocrine tumors. *J Surg Oncol*. 2007;96:397-403.
21. Partelli S, Inama M, Rinke A, Begum N, Valente R, Fendrich V, et al. Long-term outcomes of surgical management of pancreatic neuroendocrine tumors with synchronous liver metastases. *Neuroendocrinology*. 2015;102:68-76.
22. Falconi M, Bartsch DK, Eriksson B, Klöppel G, Lopes JM, O'Connor JM, et al. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors. *Neuroendocrinology*. 2012;95:120-34.
23. Eriksson B, Klöppel G, Krenning E, Ahlman H, Plöckinger U, Wiedenmann B, et al. Consensus guidelines for the management of patients with digestive neuroendocrine tumors--well-differentiated jejunal-ileal tumor/carcinoma. *Neuroendocrinology*. 2008;87:8-19.
24. Givi B, Pommier SJ, Thompson AK, Diggs BS, Pommier RF. Operative resection of primary carcinoid neoplasms in patients with liver metastases yields significantly better survival. *Surgery*. 2006;140:891-7; discussion 897-8.
25. Zheng M, Li Y, Li T, Zhang L, Zhou L. Resection of the primary tumor improves survival in patients with gastro-entero-pancreatic neuroendocrine neoplasms with liver metastases: a SEER-based analysis. *Cancer Med*. 2019;8:5128-36.
26. Tao L, Xiu D, Sadula A, Ye C, Chen Q, Wang H, et al. Surgical resection of primary tumor improves survival of pancreatic neuroendocrine tumor with liver metastases. *Oncotarget*. 2017;8:79785-92.
27. Chen Q, Li K, Rhodin KE, Masoud SJ, Lidsky ME, Cai J, et al. Primary tumor resection improves survival of gastrointestinal neuroendocrine carcinoma patients with nonresected liver metastases. *J Surg Oncol*. 2023;127:945-5.